Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Bo Ryung, Park"'
Autor:
Seung Bum Lee, Joonho Jeong, Jae Ho Park, Seok Won Jung, In Du Jeong, Sung-Jo Bang, Jung Woo Shin, Bo Ryung Park, Eun Ji Park, Neung Hwa Park
Publikováno v:
Clinical and Molecular Hepatology, Vol 26, Iss 3, Pp 364-375 (2020)
Background/Aims Low-level viremia (LLV) after nucleos(t)ide analog treatment was presented as a possible cause of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). However, detailed information on patients’ adherence in the
Externí odkaz:
https://doaj.org/article/44bdc012beae4b4caff73e537cd7a7cd
Autor:
Seung Bum Lee, Jung Woo Shin, Eun Ji Park, Neung Hwa Park, Joonho Jeong, Bo Ryung Park, Seok Won Jung, Min-Ju Kim
Publikováno v:
Digestive Diseases and Sciences. 66:1739-1750
Adherence to medication and maintained virologic response (MVR) are related to the risk of adverse clinical outcomes. This study aimed to compare the efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) in relation to the adverse clini
Autor:
Neung Hwa Park, Sung-Jo Bang, Byung Uk Lee, Jung Woo Shin, Jae Ho Park, In Du Jeong, Seok Won Jung, Bo Ryung Park, Byung Gyu Kim
Publikováno v:
Digestive Diseases and Sciences. 62:2908-2914
The clinical course of chronic hepatitis B (CHB) patients with partial virologic response (PVR) during tenofovir disoproxil fumarate (TDF) therapy remains unclear. We retrospectively investigated the long-term clinical outcomes of TDF treatment in nu
Autor:
Seok Won Jung, Shi Jung Sung, Sung-Jo Bang, Byung Uk Lee, Min-Ho Kim, In Du Jeong, Chang Jae Kim, Neung Hwa Park, Bo Ryung Park, Eun Hye Kim, Jung Woo Shin, Jae Ho Park, Jae Hee Kim, J. H. Park, Byung Gyu Kim
Publikováno v:
Journal of Gastroenterology and Hepatology. 30:1514-1521
Background and Aim In the past decade, many chronic hepatitis B (CHB) patients have undergone sequential treatment with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) to manage antiviral resistance or insufficient suppression of HBV-DNA. Very
Autor:
Jongeun Lee, Chang Jae Kim, Seok Won Jung, Eun-Soon Shin, Young-Hwa Chung, Neung Hwa Park, Jung Woo Shin, Bo Ryung Park, Jeong A. Kim
Publikováno v:
Hepatology. 59:1912-1920
Our goal was to determine whether single-nucleotide polymorphisms (SNPs) of telomere maintenance genes influence the development and clinical outcomes of patients with hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). We evaluated 20
Autor:
Hyeong Uk Ju, Jung Woo Shin, Byung Gyu Kim, Bo Ryung Park, Sung-Jo Bang, In Du Jeong, Jae Ho Park, Seok Won Jung, Neung Hwa Park, Min-Ho Kim, Chang Jae Kim
Publikováno v:
Digestive and Liver Disease. 45:600-605
Background/Aims The clinical course of patients with insufficient virologic suppression diagnosed with chronic hepatitis B undergoing entecavir therapy is unclear. Methods We retrospectively investigated the long-term clinical outcomes of entecavir t
Autor:
Jung Woo Shin, In Du Jeong, Neung Hwa Park, Byung Gyu Kim, Seok Won Jung, Sung-Jo Bang, Bo Ryung Park, Chang Jae Kim, Sang Jin Lee
Publikováno v:
Scandinavian Journal of Gastroenterology. 47:601-606
CD137, a member of the tumor necrosis factor receptor family, generates co-stimulatory signals leading to T-cell activation and proliferation for viral eradication. We examined the expression kinetics of CD137 to validate whether it can affect treatm
Autor:
Bo Ryung Park, Jae Hee Seo, Jung Woo Shin, Seok Won Jung, Chang Woo Nam, Yang Won Na, Neung Hwa Park
Publikováno v:
Journal of Surgical Oncology. 97:567-571
Objective Underlying mechanism of mitotic checkpoint gene mitosis arrest deficiency 1 (MAD1) in human hepatocellular carcinoma (HCC) is rarely known. Materials and Methods We studied genetic change of the MAD1 gene as well as protein expression in 44
Autor:
Byung Gyu, Kim, Seok Won, Jung, Eun Hye, Kim, Jae Hee, Kim, Ju Hwan, Park, Shi Jung, Sung, Bo Ryung, Park, Min-Ho, Kim, Chang Jae, Kim, Byung Uk, Lee, Jae Ho, Park, In Du, Jeong, Sung-Jo, Bang, Jung Woo, Shin, Neung Hwa, Park
Publikováno v:
Journal of gastroenterology and hepatology. 30(10)
In the past decade, many chronic hepatitis B (CHB) patients have undergone sequential treatment with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) to manage antiviral resistance or insufficient suppression of HBV-DNA. Very limited data are av
Autor:
Min-Ho Kim, Byung Gyu Kim, Jung Woo Shin, Chang Jae Kim, Neung Hwa Park, Bo Ryung Park, Sung-Jo Bang, Byung Uk Lee, Jae Ho Park, Seok Won Jung, In Du Jeong
Publikováno v:
Clinical therapeutics. 37(7)
In chronic hepatitis B patients, lamivudine (LAM) and adefovir (ADV) combination therapy is commonly used as a rescue therapy for LAM resistance, but it often results in incomplete viral suppression. We investigated the antiviral efficacy of tenofovi